급성 신손상 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Acute Kidney Injury Therapeutics Market size is expected to reach USD 3.42 Billion in 2034 from USD 1.62 Billion (2025) growing at a CAGR of 8.67% during 2026-2034.

The global acute kidney injury therapeutics market has grown as healthcare systems focus on improving treatments for kidney-related conditions. Acute kidney injury is a sudden loss of kidney function that can occur due to infections, medications, or other medical complications. Effective treatment is essential to restore kidney function and prevent long-term health problems.

Several factors are driving the growth of the acute kidney injury therapeutics market. Increasing prevalence of chronic diseases such as diabetes and hypertension has raised the risk of kidney complications. Advances in diagnostic technologies allow earlier detection of kidney injury, improving treatment outcomes. Pharmaceutical research is also developing new therapeutic approaches for kidney disease management.

In the future, the acute kidney injury therapeutics market is expected to expand as research into kidney diseases continues. Innovations in drug development and treatment protocols will improve patient outcomes. Growing healthcare investments and increased awareness of kidney health will further support market growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Prerenal Acute Kidney Injury
• Intrinsic Renal Acute Kidney Injury
• Postrenal Acute Kidney Injury

By Treatment

• Therapy
• Drug

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Pfizer Inc, Roche, Novartis AG, Sanofi, Merck Co, Inc, AstraZeneca, BristolMyers Squibb, Amgen Inc, Gilead Sciences, Eli Lilly and Company, AbbVie Inc, Baxter International Inc, Fresenius Medical Care AG Co KGaA, Braun Melsungen AG, Asahi Kasei Medical Co, Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ACUTE KIDNEY INJURY THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Prerenal Acute Kidney Injury Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Intrinsic Renal Acute Kidney Injury Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Postrenal Acute Kidney Injury Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ACUTE KIDNEY INJURY THERAPEUTICS MARKET: BY TREATMENT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment
• 5.2. Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Drug Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ACUTE KIDNEY INJURY THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ACUTE KIDNEY INJURY THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Treatment
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Treatment
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Treatment
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Treatment
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Treatment
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ACUTE KIDNEY INJURY THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Pfizer Inc
  • 9.2.2 Roche
  • 9.2.3 Novartis AG
  • 9.2.4 Sanofi
  • 9.2.5 Merck & Co.Inc
  • 9.2.6 AstraZeneca
  • 9.2.7 Bristol-Myers Squibb
  • 9.2.8 Amgen Inc
  • 9.2.9 Gilead Sciences
  • 9.2.10 Eli Lilly And Company
  • 9.2.11 AbbVie Inc
  • 9.2.12 Baxter International Inc
  • 9.2.13 Fresenius Medical Care AG & Co. KGaA
  • 9.2.14 Braun Melsungen AG
  • 9.2.15 Asahi Kasei Medical Co.Ltd